Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
AssigneeYeda Research and Development Co. Ltd.
InventorsDeborah FASS, Sarel FLEISHMAN, Lev KHMELNITSKY, Ariel TENNENHOUSE
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.
Claims31
A humanized antibody that specifically binds human Quiescin Sulfhydryl Oxidase 1 (QSOX1), or an antigen-binding fragment thereof, wherein the humanized antibody or the antigen-binding fragment comprises three complementarity-determining regions (CDRs) of a heavy-chain (HC) variable region wherein, -HC CDR1 comprises the sequence VSGFSLTGYGVN (SEQ ID NO:
- 3);
- HC CDR2 comprises the sequence WLGMIWGDGRTD (SEQ ID NO:
- 4);
- HC CDR3 comprises the sequence ASDYYGSGSFAY (SEQ ID NO:
- 5);
- and three CDRs of a light-chain (LC) variable region, wherein LC CDR1 comprises the sequence KASQDVSTAVA (SEQ ID NO:
- 6);
- LC CDR2 comprises the sequence LLIHSASYRY (SEQ ID NO:
- 7);
- and LC CDR3 comprises the sequence QQHYSIPLT (SEQ ID NO:
- 8), and wherein said antibody or antigen-binding fragment has an inhibitory constant (Ki) of 5×10−9M or lower to human QSOX1.
2-5. (canceled)
7-8. (canceled)
(canceled)
15-16. (canceled)
(canceled)
(canceled)
24-30. (canceled)
(canceled)
38-39. (canceled)
(canceled)
43-44. (canceled)
Dependencies are inferred from the claim text.